SCHEMBL459626

SCHEMBL459626

COc1ccc(-c2ccc3c(c2)CC(C(=O)NO)CC3)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.50
MTNR1B P49286 1/20 0.50
CA1 P00915 3/20 0.47
CA2 P00918 3/20 0.47
ACHE P22303 3/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
DRD2 P14416 2/20 0.45
DRD3 P35462 2/20 0.45
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP13 P45452 2/20 0.43
NPY5R Q15761 1/20 0.43
HSD17B3 P37058 1/20 0.43
FAAH O00519 2/20 0.43
MCHR1 Q99705 1/20 0.43
ADORA3 P0DMS8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436970 0.93 MTNR1A (0.49) MTNR1AMTNR1BCA1CA2ACHE
SCHEMBL10197641 0.91 MTNR1A (0.60) MTNR1AMTNR1BCA1CA2ACHE
SCHEMBL10197736 0.90 HDAC1 (0.53) MTNR1AMTNR1BCA1CA2ACHE
SCHEMBL10265076 0.88 ABL1 (0.41) MTNR1AMTNR1BCA1CA2ACHE
SCHEMBL460142 0.88 NPY5R (0.47) MTNR1AMTNR1BACHENPC1RAB9A
SCHEMBL460083 0.88 HDAC8 (0.47) NPY5R
SCHEMBL460204 0.87 MTNR1A (0.46) MTNR1AMTNR1BCA1CA2ACHE
SCHEMBL10260016 0.85 FAAH (0.51) FAAH
SCHEMBL346286 0.85 CA1 (0.56) MTNR1AMTNR1BCA1CA2ACHE
SCHEMBL438436 0.84 TDP2 (0.44) MTNR1AMTNR1BNPY5RFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243334-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012320-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
WO-2012012320-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015942-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 MTNR1A 1579/4885MTNR1B 1240/4885CA1 400/4885
US-20140243334-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, H1-3, H1-5 MTNR1A 1442/4885MTNR1B 1160/4885CA1 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.